New product newswire: February 20, 2006

The new approval is in line with recommendations that suggest booster vaccination for older adults and patients aged 12 to 64 with at least 1 or more underlying risk factors.

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

The replacement therapy is indicated for patients 5 years and older, marking the first approval for an oral solution form of hydrocortisone.

This designation follows Hadlima’s low-concentration prefilled syringes and single-dose vials, which were designated in June 2024.

Ustekinumab is a medication used to treat and manage inflammatory conditions, including psoriasis, psoriatic arthritis, and inflammatory bowel disease.

The supplemental new drug application for roflumilast (Zoryve) is approved for adult and pediatric patients 12 years and older.